The U.S. Court of Appeals for the Federal Circuit reinstated patent claims covering Allergan USA Inc.'s bowel treatment drug Viberzi (eluxadoline), reversing a lower court that had invalidated the claims for not meeting obviousness-type double patenting or written description requirements. However, the appellate court said the district court “can, and should, address any other grounds of invalidity raised … at trial that are adequately supported by the record.”
In what represents the first patenting to emerge in the assignee’s name, additional protection is being sought for Rapidpulse Inc.’s aspiration system, which delivers high-frequency pulsed vacuum forces to increase the efficiency of aspiration thrombectomy and remove thrombus from the neurovasculature.
In what represents the first patenting to emerge from Endeavor Med Inc., its founder and chief executive officer, Imran Faruqi, describes their development of a novel device capable of providing non-invasive cardiac pacing, defibrillation, and cardioversion, and which uses pacing currents at less than half that required by traditional chest pads.
In what represents just the second PCT filing to have emerged from Valar Labs Inc., the company’s co-founders – Joshi Anirudh, Viswesh Krishna, and Damir Vrabac – describe their development of an AI-derived histologic signature for predicting patient outcomes to treatments for pancreatic cancer.
In Pumpkinseed Technologies Inc.’s first public patenting, the company’s co-founders describe their development of new proteomics platform that merges nanotechnology, biochemistry, silicon photonics and machine learning for high-resolution phenotyping to deliver new biological insights.
The proposal to overhaul the use of terminal disclaimers in U.S. patent filings won over no fans among former directors of the U.S. Patent and Trademark Office, but device and drug makers, too, are concerned about the proposal.
The first patenting to be published in the name of Wave View Imaging Inc. sees its co-founders file for additional protection of their imaging technology which can be used to monitor breast cancer treatment.
In what represents the first patenting to emerge from Braincapture ApS, its chief executive officer, Tue Lehn-Schiøler, describes the development of a low-cost, portable electroencephalogram device designed to enhance neurological diagnostics in underserved communities around the world.
In just the second PCT filing published in the name of Newmanbrain SL, co-founders Carlos Belmonte and Joaquin Ibañez seek specific protection for the use of Newmanbrain’s functional near infrared spectroscopy system, Theia, in the diagnosis of attention deficit/hyperactivity disorder.
The U.S. Patent and Trademark Office has provided updated guidance on the question of patent subject matter eligibility for inventions that rely on artificial intelligence, stating that a patent claim that does little more than recite an abstract idea is not subject-matter eligible.